Stock Events

Stock Events

Finch Therapeutics Group 

$9.2
5
-$0.09-0.97% Friday 20:00

Statistics

Day High
11.91
Day Low
5.01
52W High
16.1
52W Low
2
Volume
71,791
Avg. Volume
3,683
Mkt Cap
14.78M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

13MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Next
Next
999
333
-333
-999
Expected EPS
N/A
Actual EPS
N/A

Financials

-69,863.55%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
214,000Revenue
-149.51MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow FNCH. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regenxbio
RGNX
Mkt Cap645.07M
REGENXBIO Inc. is involved in gene therapy, which overlaps with Finch Therapeutics' approach to treating chronic diseases, including those related to the microbiome.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals Incorporated works on creating transformative medicines for people with serious diseases, including genetic therapies that could compete with Finch's microbiome-based treatments.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics AG focuses on gene editing, a cutting-edge area of biotech that could rival Finch Therapeutics' microbiome-based approaches in treating genetic disorders.
Novartis
NVS
Mkt Cap237.61B
Novartis AG, a large pharmaceutical company, has a broad interest in innovative therapeutic approaches, including gene and cell therapies, which could compete with Finch's microbiome therapies.
Biogen
BIIB
Mkt Cap22.63B
Biogen Inc. has a strong focus on neurodegenerative diseases, an area where Finch Therapeutics could make inroads with its microbiome-based treatments.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, Inc. is known for its work in antiviral drugs but is expanding into other therapeutic areas, potentially competing with Finch Therapeutics in the microbiome space.
AMGEN
AMGN
Mkt Cap160.66B
Amgen Inc. is a biotech giant that explores various therapeutic areas, including those that could overlap with Finch Therapeutics' focus on microbiome and chronic diseases.
Pfizer
PFE
Mkt Cap140.15B
Pfizer Inc., with its wide range of pharmaceutical products and research into new therapies, could become a competitor as it explores the microbiome's role in health and disease.

About

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.
Show more...
CEO
Mr. Matthew P. Blischak J.D.
Employees
1
Country
US
ISIN
US31773D2009

Listings

OTC Link
US
FNCHQ
OTCM
US
FNCH

0 Comments

Share your thoughts

FAQ

What is Finch Therapeutics Group stock price today?▼
The current price of FNCH is $9.2 USD — it has decreased by -0.97% in the past 24 hours. Watch Finch Therapeutics Group stock price performance more closely on the chart.
What is Finch Therapeutics Group stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Finch Therapeutics Group stocks are traded under the ticker FNCH.
Is Finch Therapeutics Group stock price growing?▼
FNCH stock has risen by +6.98% compared to the previous week, the month change is a -26.49% fall, over the last year Finch Therapeutics Group has showed a -35.44% decrease.
What is Finch Therapeutics Group market cap?▼
Today Finch Therapeutics Group has the market capitalization of 14.78M
When is the next Finch Therapeutics Group earnings date?▼
Finch Therapeutics Group is going to release the next earnings report on May 13, 2026.
What is Finch Therapeutics Group revenue for the last year?▼
Finch Therapeutics Group revenue for the last year amounts to 214,000 USD.
What is Finch Therapeutics Group net income for the last year?▼
FNCH net income for the last year is -149.51M USD.
How many employees does Finch Therapeutics Group have?▼
As of April 01, 2026, the company has 1 employees.
In which sector is Finch Therapeutics Group located?▼
Finch Therapeutics Group operates in the Health Care sector.
When did Finch Therapeutics Group complete a stock split?▼
The last stock split for Finch Therapeutics Group was on June 12, 2023 with a ratio of 1:30.
Where is Finch Therapeutics Group headquartered?▼
Finch Therapeutics Group is headquartered in Boston, US.